Novo Nordisk expands access to weight-loss drug Wegovy through telehealth partnerships, offering discounted rates as compounded GLP-1 alternatives become less available.
Coca-Cola's Q1 revenue falls, but shares rise on strong outlook and growth in emerging markets.
First Solar cuts 2025 outlook after Q1 earnings miss, citing tariffs and market pressures, but remains optimistic about long-term growth prospects.
Novo Nordisk expands access to weight-loss drug Wegovy through telehealth partnerships, offering discounted rates as compounded GLP-1 alternatives become less available.
Coca-Cola's Q1 revenue falls, but shares rise on strong outlook and growth in emerging markets.
First Solar cuts 2025 outlook after Q1 earnings miss, citing tariffs and market pressures, but remains optimistic about long-term growth prospects.